Analyst Price Target is $19.50
▲ +277.18% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. The average price target is $19.50, with a high forecast of $50.00 and a low forecast of $3.00. The average price target represents a 277.18% upside from the last price of $5.17.
Current Consensus is
The current consensus among 7 investment analysts is to hold stock in Atara Biotherapeutics. This rating has held steady since April 2022, when it changed from a Buy consensus rating.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.